Nutex Health Overview
Latest ROE for Nutex Health: 35.46% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow35.46%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for NUTX is 35.46%. That is above the Consumer Staples sector average of 13.7%. Investors often review this figure alongside Nutex Health's historical trend and sector peers before judging valuation or financial health.
Against Consumer Staples companies, NUTX currently prints 35.46% for ROE, while the sector average sits near 13.7%. That is roughly 158.9% above the sector mean. Large gaps often invite a closer look at Nutex Health's growth, margins, and balance sheet.
Return on Equity shows how effectively Nutex Health converts resources into returns. At 35.46%, NUTX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting NUTX's ROE (35.46%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Nutex Health's ROE against similar Consumer Staples names. You can also browse sector and industry screens on Stockcircle for a broader set of Consumer Staples companies and their key multiples and fundamentals.
